摘要
Ulcerative colitis and Crohn’s disease are the main entities of inflammatory bowel disease characterized by chronic remittent inflammation of the gastrointestinal tract.The incidence and prevalence are on the rise worldwide,and the heterogeneity between patients and within individuals over time is striking.The progressive advance in our understanding of the etiopathogenesis coupled with an unprecedented increase in therapeutic options have changed the management towards evidence-based interventions by clinicians with patients.This guideline was stimulated and supported by the Emirates Gastroenterology and Hepatology Society following a systematic review and a Delphi consensus process that provided evidence-and expert opinion-based recommendations.Comprehensive up-to-date guidance is provided regarding diagnosis,evaluation of disease severity,appropriate and timely use of different investigations,choice of appropriate therapy for induction and remission phase according to disease severity,and management of main complications.
基金
Supported by Emirates Gastroenterology and Hepatology Society,No.001802.
作者简介
Corresponding author:Vito Annese,MD,PhD,Assistant Professor,Director,Department of Gastroenterology,Valiant Clinic,City Walk 13th Street,Dubai,United Arab Emirates.vitoannese1@gmail.com,ORCID number:0000-0002-0082-892X;ORCID number:Maryam Alkhatry,0000-0002-1427-7831;ORCID number:Ahmad Al-Rifai,0000-0003-1710-7114;ORCID number:Filippos Georgopoulos,0000-0003-0634-4026;ORCID number:Ahmad N Jazzar,0000-0002-4555-7067;ORCID number:Ahmed M Khassouan,0000-0001-8738-9490;ORCID number:Zaher Koutoubi,0000-0001-7894-9900;ORCID number:Rahul Nathwani,0000-0001-0080-891P;ORCID number:Mazen S Taha,0000-0002-2264-8559;ORCID number:Jimmy K Limdi,0000-0002-1039-6251。
